Andrew Hirsch - 30 Aug 2023 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role: President & CEO, Director
Signature: /s/ Jolie M. Siegel, Attorney-in-Fact
Issuer symbol: CCCC
Transactions as of: 30 Aug 2023
Net transactions value: -$6,461
Form type: 4
Filing time: 31 Aug 2023, 16:13:51 UTC
Previous filing: 05 Jun 2023
Next filing: 19 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCCC	Common Stock	Options Exercise		+7,500	+6.9%		116,106	30 Aug 2023	Direct	F1
transaction	CCCC	Common Stock	Tax liability	$6,461	-2,205	-1.9%	$2.93	113,901	30 Aug 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCCC	Performance Restricted Stock Units	Options Exercise	$0	-7,500	-12%	$0.000000	55,000	30 Aug 2023	Common Stock	7,500		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 15,000 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
F2	Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of PRSUs and does not represent a sale by the Reporting Person.